- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-CP2A6/ CYP2A6/ CPA6 functional antibody
Anti-CP2A6/ CYP2A6/ CPA6 functional antibody for cell culture, ELISA & in-vivo assay
Go to CYP2A6/CYP2A6 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T06455-Ab-1/ GM-Tg-hg-T06455-Ab-2 | Anti-Human CYP2A6 monoclonal antibody | Human |
| GM-Tg-rg-T06455-Ab-1/ GM-Tg-rg-T06455-Ab-2 | Anti-Rat CYP2A6 monoclonal antibody | Rat |
| GM-Tg-mg-T06455-Ab-1/ GM-Tg-mg-T06455-Ab-2 | Anti-Mouse CYP2A6 monoclonal antibody | Mouse |
| GM-Tg-cynog-T06455-Ab-1/ GM-Tg-cynog-T06455-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CYP2A6 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T06455-Ab-1/ GM-Tg-felg-T06455-Ab-2 | Anti-Feline CYP2A6 monoclonal antibody | Feline |
| GM-Tg-cang-T06455-Ab-1/ GM-Tg-cang-T06455-Ab-2 | Anti-Canine CYP2A6 monoclonal antibody | Canine |
| GM-Tg-bovg-T06455-Ab-1/ GM-Tg-bovg-T06455-Ab-2 | Anti-Bovine CYP2A6 monoclonal antibody | Bovine |
| GM-Tg-equg-T06455-Ab-1/ GM-Tg-equg-T06455-Ab-2 | Anti-Equine CYP2A6 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T06455-Ab-1/ GM-Tg-hg-T06455-Ab-2; GM-Tg-rg-T06455-Ab-1/ GM-Tg-rg-T06455-Ab-2; GM-Tg-mg-T06455-Ab-1/ GM-Tg-mg-T06455-Ab-2; GM-Tg-cynog-T06455-Ab-1/ GM-Tg-cynog-T06455-Ab-2; GM-Tg-felg-T06455-Ab-1/ GM-Tg-felg-T06455-Ab-2; GM-Tg-cang-T06455-Ab-1/ GM-Tg-cang-T06455-Ab-2; GM-Tg-bovg-T06455-Ab-1/ GM-Tg-bovg-T06455-Ab-2; GM-Tg-equg-T06455-Ab-1/ GM-Tg-equg-T06455-Ab-2 |
| Products Name | Anti-CYP2A6 monoclonal antibody |
| Format | mab |
| Target Name | CYP2A6 |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-CYP2A6 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-T06455-Ag-1 | Recombinant multi-species CP2A6/ CYP2A6/ CPA6 protein |
| ORF Viral Vector | pGMAP000463 | Human CYP2A6 Adenovirus plasmid |
| ORF Viral Vector | vGMAP000463 | Human CYP2A6 Adenovirus particle |
Target information
| Target ID | GM-T06455 |
| Target Name | CYP2A6 |
| Gene ID | 1548 |
| Gene Symbol and Synonyms | CPA6,CYP2A,CYP2A3,CYP2A6,CYPIIA6,P450C2A,P450PB |
| Uniprot Accession | P11509 |
| Uniprot Entry Name | CP2A6_HUMAN |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category | Therapeutics Target |
| Disease | Cancer |
| Gene Ensembl | ENSG00000255974 |
| Target Classification | Tumor-associated antigen (TAA) |
The target: CYP2A6, gene name: CYP2A6, also named as CPA6, CYP2A, CYP2A3, CYPIIA6, P450C2A, P450PB. This gene, CYP2A6, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by phenobarbital. The enzyme is known to hydroxylate coumarin, and also metabolizes nicotine, aflatoxin B1, nitrosamines, and some pharmaceuticals. Individuals with certain allelic variants are said to have a poor metabolizer phenotype, meaning they do not efficiently metabolize coumarin or nicotine. This gene is part of a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q. The gene was formerly referred to as CYP2A3; however, it has been renamed CYP2A6. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
